Roivant Sciences (ROIV) EPS (Weighted Average and Diluted) (2021 - 2025)
Roivant Sciences (ROIV) reported EPS (Weighted Average and Diluted) of -$0.38 for Q4 2025, down 265.22% on a YoY basis from $0.23 in Q4 2024, and down 123.53% quarter-over-quarter from -$0.17 in Q3 2025.
Roivant Sciences (ROIV) EPS (Weighted Average and Diluted) (2021 - 2025) Analysis & Trends
Roivant Sciences has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.38 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 265.22% year-over-year to -$0.38; the trailing twelve-month figure through Dec 2025 stood at -$0.65 (down 110.6% YoY), and the FY2026 full-year result was -$0.54, up 28.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.38, down from -$0.17 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $6.03 in Q4 2023, with the low at -$0.49 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.16 across 5 years, with a median of -$0.32 in 2021.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) soared 1330.61% — and 2025, when it sank 375.0%.
- Roivant Sciences' EPS (Weighted Average and Diluted) stood at -$0.41 in 2021, then fell by 19.51% to -$0.49 in 2022, then surged by 1330.61% to $6.03 in 2023, then plunged by 96.19% to $0.23 in 2024, then slumped by 265.22% to -$0.38 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.38 (Q4 2025), -$0.17 (Q3 2025), and -$0.33 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.17 |
| Jun 30, 2025 | -0.33 |
| Dec 31, 2024 | 0.23 |
| Sep 30, 2024 | -0.25 |
| Jun 30, 2024 | 0.12 |
| Dec 31, 2023 | 6.03 |
| Sep 30, 2023 | -0.28 |
| Jun 30, 2023 | -0.38 |
| Dec 31, 2022 | -0.49 |
| Sep 30, 2022 | -0.42 |
| Jun 30, 2022 | -0.48 |
| Dec 31, 2021 | -0.41 |
| Sep 30, 2021 | -0.32 |
| Jun 30, 2021 | -0.13 |